102390-36-3 Usage
Uses
Used in Medicinal Chemistry:
(1r,4r)-4-(dibenzylamino)cyclohexane-1-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structure and potential biological activities. The presence of the dibenzylamino group may impart specific properties to the molecule, enhancing its interactions with biological targets and contributing to its therapeutic effects.
Used in Drug Design and Development:
In the pharmaceutical industry, (1r,4r)-4-(dibenzylamino)cyclohexane-1-carboxylic acid is utilized as a building block in drug design and development. Its cyclohexane-1-carboxylic acid moiety suggests potential interactions with biological targets, which can be harnessed to create new drugs with improved efficacy and selectivity.
Used in Research and Development:
(1r,4r)-4-(dibenzylamino)cyclohexane-1-carboxylic acid serves as a valuable compound in research and development settings. Scientists can use this chiral molecule to study its interactions with biological systems, potentially leading to the discovery of new therapeutic agents or a better understanding of biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 102390-36-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,3,9 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 102390-36:
(8*1)+(7*0)+(6*2)+(5*3)+(4*9)+(3*0)+(2*3)+(1*6)=83
83 % 10 = 3
So 102390-36-3 is a valid CAS Registry Number.
102390-36-3Relevant academic research and scientific papers
HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
-
Paragraph 0805, (2021/02/05)
The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
-
, (2018/04/27)
A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS
-
, (2011/10/13)
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
